Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KTX-101
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Kuria Therapeutics
Deal Size : $67.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of SCOHIA’s internally discovered novel Nrf2 activators, for prevention and/or treatment of eye and skin diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 27, 2022
Lead Product(s) : KTX-101
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Kuria Therapeutics
Deal Size : $67.0 million
Deal Type : Licensing Agreement
Reset All
